ARTICLE | Emerging Company Profile

Vascular Magnetics: A long-term force

Vascular Magnetics developing magnetically delivered paclitaxel for PAD

April 30, 2012 7:00 AM UTC

Drug-eluting stents were developed to better reduce restenosis compared with bare-metal stents following procedures like angioplasty, but for many patients neither of these interventions is effective long term. Vascular Magnetics Inc. is developing drug-loaded magnetic particles to reduce restenosis rates by delivering higher doses of anti-restenotic drugs than drug-eluting stents.

PAD is treated with angioplasty followed by a bare-metal or drug-eluting stent. According to co-founder, President and COO Richard Woodward, 20-40% of arteries become re-obstructed each year...